Hearing handicap in patients with chronic kidney disease: a study of the different classifications of the degree of hearing loss

Costa, Klinger Vagner Teixeira da; Ferreira, Sônia Maria Soares; Menezes, Pedro de Lemos

doi:10.1016/j.bjorl.2016.08.008

Cited by 11 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic kidney disease (CKD), which has multiple etiologies, can evolve with progressive hearing loss, representing yet another disability for kidney patients and compromising their quality of life. Moreover, the use of certain drugs for patients with CKD may worsen auditory function and be an aggravating factor for hearing loss [8].…”

Section: Hearing Lossesmentioning

confidence: 99%

“…At the enzyme level, exposure to noise increases oxidase NADPHA (NOX) levels in the cochlea and a decline in SOD increases susceptibility to acoustic lesions. The accumulation of ROS subsequently triggers a complex cascade of biochemical processes including activation of c-Jun Nterminal kinase (JNK) and p38MAPK, the release of cytochrome and mitochondria and proca spase activation [3,8,9] (intrinsic apoptotic pathway) [21,22].…”

Section: Noise-induced Hearing Lossmentioning

confidence: 99%

“…The primary lesion site of hearing loss in CKD is the cochlea [49]; however, some studies also report the involvement of retrocochlear pathways and the central nervous system [41,50]. Hearing loss normally occurs symmetrically at high frequencies [8,43,51].…”

Section: Hearing Loss Associated With Chronic Kidney Diseasementioning

confidence: 99%

See 2 more Smart Citations

Hearing Loss at High Frequencies and Oxidative Stress: A New Paradigm for Different Etiologies

Costa¹,

Andrade²,

Cavalcanti³

et al. 2018

An Excursus Into Hearing Loss

Self Cite

View full text Add to dashboard Cite

The clinical assessment of hearing loss has been transformed and revised in terms of interpreting the characteristics of patterns found in relation to the relative frequency of certain diseases. However, increasing the threshold to 4 kHz as a starting point for hearing loss has shown to be common to different diseases such as noise-induced hearing loss. In noise-induced hearing loss, for example, six mechanisms can be considered: conversion of sound pressure level into hearing level, vascular failure in the cochlear region responsible for hearing at 4 kHz, sound wave propagation velocity is very high and causes the displacement amplitude in the cochlear duct, the structure anatomy of the cochlea causes a collision of fluids in the first curve of the cochlea, characteristics of auricular pavilion resonance and external auditory canal, and sound attenuation of the acoustic reflex. It is hoped that this new paradigm for the different hearing losses will result in a different approach to the physiological changes that affect the auditory system in the form of high-frequency hearing loss. As such, preventing, treating, and avoiding exacerbations are possibilities to be investigated in order to guarantee efficient communication and quality of life for individuals.

show abstract

Section: Hearing Lossesmentioning

confidence: 99%

Section: Noise-induced Hearing Lossmentioning

confidence: 99%

See 1 more Smart Citation

Hearing Loss at High Frequencies and Oxidative Stress: A New Paradigm for Different Etiologies

Costa¹,

Andrade²,

Cavalcanti³

et al. 2018

An Excursus Into Hearing Loss

Self Cite

View full text Add to dashboard Cite

show abstract

“…HL is more prevalent in patients with chronic kidney disease (CKD) than in the general population. 5 8 While the overall prevalence of HL with CKD is 40%–75% in adults and about 40% in children, 9 10 SNHL is more common than CHL in this population, 8 11 with the prevalence of SNHL in adult patients estimated to be 20%–87% and 29%–40% in children. 10 12 Several potential hypotheses have been proposed to explain the higher prevalence of HL in patients with CKD; one of them is that the kidney and the stria vascularis of the cochlea share physiologic, ultrastructural, and antigenic characteristics that could underlie the link between CKD and HL.…”

Section: Introductionmentioning

confidence: 96%

Renal Syndromic Hearing Loss is Common in Childhood-onset Chronic Kidney Disease

Kim

Lee

et al. 2020

J Korean Med Sci

View full text Add to dashboard Cite

Background: Hearing loss (HL) in children may adversely affect their development. HL is more prevalent in patients with chronic kidney disease (CKD) than in the general population. This study evaluated the prevalence of HL and its underlying diseases in patients with childhood-onset in CKD. Methods: In this retrospective study of a tertiary referral center, childhood-onset CKD patients (stage 2-5, age at onset of renal symptom < 18 years) were recruited. We referred to the "renal" syndromic HL as cases with genetic or syndromic diseases, or extra-renal anomalies in addition to HL and CKD. Results: A total of 421 patients (male:female = 279:142) were reviewed according to the causes of CKD: congenital anomalies of the kidney and urinary tract (CAKUT; n = 184, 43.7%), glomerulopathies (GP; n = 105, 24.9%), cystic kidney diseases (CYST; n = 39, 9.3%), perinatal problems (PP; n = 29, 6.9%), and others (n = 64, 15.2%). HL was detected in 82 (19.5%) patients, including 51 (12.1%) patients with sensorineural hearing loss (SNHL), 30 (7.1%) with conductive hearing loss (CHL), and 1 patient with mixed HL. The prevalence of HL in each group was as follows: 16.8% in the CAKUT group, 28.6% in the GP group, 12.8% in the CYST group, 24.1% in the PP group, and 14.1% in the others group. HL was more common in higher CKD stages, especially CHL in end-stage renal disease. SNHL was more prevalent in CKD from GP. Of the 82 patients with HL, 50% had renal syndromic HL: 58.8% of SNHL and one-third of CHL were renal syndromic HL. Conclusion: One-fifth of the childhood-onset CKD had HL. Collectively, renal syndromic HL comprised half of the HL in this study. To improve the quality of life in patients with childhood-onset CKD, we suggest that HL should be considered, requiring surveillance, and if necessary, early intervention.

show abstract

“…However, most hearing losses that occur in CKD are not genetic and have been linked to the anatomical, physiological, pathological, and pharmacological similarities between the nephron of the kidney and the microvascular system of the cochlea (stria vascularis). 5 The hearing impairments in patients with CKD are greater than in the general population, even in children, and is most severe in the high-frequency range. 6,7 Torban and Goodyer 8 reported that following a therapeutic dose of the chemotherapeutic, cisplatin, 50% of the drug is excreted in urine within 24 hours, but cells of the S3 segment of the renal proximal tubules 9 and marginal cells of the auditory stria vascularis 10 appear to accumulate the drug at concentrations greater than plasma and initiate cyclin-dependent kinase (CDK2) pathways to programmed cellular death.…”

Section: Introductionmentioning

confidence: 99%

Predicting the Need for a Tier II Ototoxicity Study From Early Renal Function Data

et al. 2019

View full text Add to dashboard Cite

History has established that many drugs, such as the antibiotics, chemotherapies, and loop diuretics, are capable of inducing both nephrotoxicity and ototoxicity. The exact mechanisms by which cellular damage occurs remain to be fully elucidated. Monitoring the indices of renal function conducted in the Food and Drug Administration’s prescribed set of early investigational new drug (IND)–enabling studies may be the first signs of ototoxicity properties of the new drug candidate. In developing improved and efficacious new molecular entities, it is critically necessary to understand the cellular and molecular mechanisms underlying the potential ototoxic effects as early in the drug development program as possible. Elucidation of these mechanisms will facilitate the development of safe and effective clinical approaches for the prevention and amelioration of drug-induced ototoxicity prior to the first dose in man. Biomarkers for nephrotoxicity in early tier I or tier II nonclinical IND-enabling studies should raise an inquiry as to the need to conduct a full auditory function assay early in the game to clear the pipeline with a safer candidate that has a higher probability of continued therapeutic compliance once approved for distribution.

show abstract

Hearing handicap in patients with chronic kidney disease: a study of the different classifications of the degree of hearing loss

Cited by 11 publications

References 18 publications

Hearing Loss at High Frequencies and Oxidative Stress: A New Paradigm for Different Etiologies

Hearing Loss at High Frequencies and Oxidative Stress: A New Paradigm for Different Etiologies

Renal Syndromic Hearing Loss is Common in Childhood-onset Chronic Kidney Disease

Predicting the Need for a Tier II Ototoxicity Study From Early Renal Function Data

Contact Info

Product

Resources

About